ASTH Maintained by Freedom Capital Markets -- Price Target Remains $50

· gurufocus.com

Astrana Health Inc (ASTH) Analyst Rating Update On October 1, 2026, Freedom Capital Markets analyst Gene Mannheimer maintained a Buy rating for Astrana Healt

Astrana Health Inc ASTH Analyst Rating Update

On October 1, 2026, Freedom Capital Markets analyst Gene Mannheimer maintained a Buy rating for Astrana Health (A...


More AI market news · Market heatmap · StrategyVerse · Quant Research · WOBR.AI